IP Library Granted Patent US 10,064,904
Granted Patent B2
US 10,064,904 · App. 15/884,029 · Granted Sep 4, 2018

Treatment of

Inventors: Jessica Schneider (Cambridge, MA); Yun-Gi Kim (Watertown, MA); Bernat Olle (Cambridge, MA); Shilpa Reddy (Watertown, MA); Jason Norman (North Weymouth, MA); Juan Patarroyo (Lexington, MA)
Assignee: Vedanta Biosciences, Inc.
A61K35/747A23L5/00A23L33/135A61K9/0053A61K9/48A61K35/74A61K35/742A23K10/18A23K50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,064,904
App. No.
15/884,029
Granted
Sep 4, 2018
Kind
B2
Abstract

Provided herein are compositions and methods for the treatment or prevention of pathogenic infections.

Claims (12)

1. A method of treating Clostridium difficile infection in a subject, the method comprising administering a pharmaceutical composition comprising a purified bacterial mixture consisting of bacterial strains comprising 16S rDNA sequences of at least 97% sequence identity to SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:21, to the subject in an amount sufficient to treat Clostridium difficile infection.

2. The method of claim 1 , wherein the Clostridium difficile infection is a first occurrence of the Clostridium difficile infection.

3. The method of claim 1 , wherein the Clostridium difficile infection is a recurrent Clostridium difficile infection.

4. The method of claim 3 , wherein the subject has been treated with an antibiotic prior to recurrence of the Clostridium difficile infection.

5. The method of claim 1 , further comprising administering an antibiotic.

6. The method of claim 1 , wherein one or more of the bacterial strains are spore-formers.

7. The method of claim 1 , wherein the bacterial strains originate from more than one human donor.

8. The method of claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

9. The method of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.

10. The method of claim 1 , wherein the pharmaceutical composition wherein the pharmaceutical composition is in the form of a capsule.

11. The method of claim 1 , wherein the pharmaceutical composition is formulated for delivery to the colon.

12. The method of claim 1 , wherein the pharmaceutical composition further comprises one or more enteric polymers.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2023
From: OXFORD FINANCE LLC
To: VEDANTA BIOSCIENCES, INC.
Reel/Frame 063440/0569 →
SECURITY INTEREST Recorded Apr 21, 2023
From: VEDANTA BIOSCIENCES, INC.
To: ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE
Reel/Frame 063406/0052 →
SECURITY INTEREST Recorded Dec 12, 2022
From: VEDANTA BIOSCIENCES, INC.
To: OXFORD FINANCE LLC
Reel/Frame 062115/0411 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2018
From: SCHNEIDER, JESSICA; KIM, YUN-GI; OLLE, BERNAT; REDDY, SHILPA; NORMAN, JASON; PATARROYO, JUAN
To: VEDANTA BIOSCIENCES, INC.
Reel/Frame 046397/0606 →
Continuity (4)
Continuation 15630088 · Jun 22, 2017
Continuation PCTUS2017037498 · Jun 14, 2017
Provisional Application 62349914 · Jun 14, 2016
Related Publication 20180169157A1 · Jun 21, 2018
Cited By (4)
US 12,214,003 US 12,390,498 US 12,409,196 US 12,502,411